AKRO Pengajuan SEC - Akero Therapeutics, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300SI3KG74LBE2955
CIK	1744659

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Akero Therapeutics, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 8, 2025	EX-10.1	Amended and Restated Non-Employee Director Compensation Policy EXHIBIT 10.1 Akero therapeutics, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy of Akero Therapeutics, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers o
August 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Akero Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
August 8, 2025	10-Q	SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS PART I—FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements 1. Nature of the business and basis of presentation 2. Summary of significant accounting policies 4. Short and Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
August 8, 2025	EX-99.1	Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted EX-99.1 Exhibit 99.1 Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of compensated cirrhosis (F4) due to MASH and corroborating the anti-fibrot
June 4, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission F
May 12, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission F
May 12, 2025	EX-99.1	Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatme Exhibit 99.1 Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of treatment with efruxifermin (EFX) Presented two oral presentations and a poster presentation highlighting the latest data and new analyses from
May 12, 2025	10-Q	SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS PART I—FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements 1. Nature of the business and basis of presentation 2. Summary of significant accounting policies 4. Short and Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
April 28, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
February 28, 2025	EX-19.1	Insider Trading Policy Exhibit 19.1 AKERO THERAPEUTICS, INC. INSIDER TRADING POLICY This memorandum sets forth the policy of Akero Therapeutics, Inc. (the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Policy”) is designed to prevent insider trading or the appearance of impropriety, to satisfy the Com
February 28, 2025	EX-4.2	Description of Securities EXHIBIT 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Akero Therapeutics, Inc.(“Akero,” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Fourth Amended
February 28, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38
February 28, 2025	S-8	As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.
February 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 Akero Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commiss
February 28, 2025	EX-99.1	Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update — Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxi Exhibit 99.1 Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update — Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study — — Completed enrollment of the double-blinded portion of the Phase 3 SYNCHRONY Real-World Study
February 28, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Akero Therapeutics, Inc.
January 30, 2025	EX-4.1	Form of Pre-Funded Warrant. EX-4.1 Exhibit 4.1 AKERO THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [ ] Number of Shares: [ ] (subject to adjustment) Original Issue Date: January [], 2025 Akero Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ], or its p
January 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 Akero Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commissi
January 30, 2025	EX-1.1	Underwriting Agreement, dated as of January 28, 2025, by and between the Company, J.P. Morgan, Morgan Stanley and Jefferies, as representatives of the several underwriters named therein EX-1.1 Exhibit 1.1 Akero Therapeutics, Inc. 5,333,420 Shares of Common Stock, par value $0.0001 per share Pre-Funded Warrants to Purchase 1,958,247 Shares of Common Stock Underwriting Agreement January 28, 2025 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Jefferies LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Ave
January 29, 2025	424B5	Common Stock Preferred Stock Debt Securities Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-279338 Prospectus supplement (To prospectus dated May 10, 2024) 5,333,420 shares of common stock Pre-funded warrants to purchase 1,958,247 shares of common stock We are offering 5,333,420 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 1,958
January 29, 2025	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Akero Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Akero Therapeutics, Inc.
January 28, 2025	FWP	Issuer Free Writing Prospectus Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated January 27, 2025 Relating to Preliminary Prospectus Supplement Dated January 27, 2025 Registration Statement No.
January 27, 2025	424B5	Common Stock Preferred Stock Debt Securities 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No.
January 27, 2025	EX-99.1	Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study Among patients with baseline and week Exhibit 99.1 Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a
January 27, 2025	EX-99.2	Safe Harbor and Legal Disclaimers This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating Topline Preliminary Week 96 Results From Phase 2b SYMMETRY Study in Patients with Compensated Cirrhosis (F4) Due to MASH January 27, 2025 Restoring balance.
January 27, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 Akero Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction (Commission (I.R.S. Employe
January 27, 2025	EX-99.3	Safe Harbor and Legal Disclaimers This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating Corporate Presentation Restoring Balance. Renewing Life. January 2025 Exhibit 99.3 Safe Harbor and Legal Disclaimers This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including b
November 14, 2024	SC 13G/A	AKRO / Akero Therapeutics, Inc. / RTW INVESTMENTS, LP - AKERO THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p24-3263sc13ga.htm AKERO THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this stateme
November 13, 2024	SC 13G/A	AKRO / Akero Therapeutics, Inc. / ALKEON CAPITAL MANAGEMENT LLC - AKERO THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p24-3279sc13ga.htm AKERO THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Akero Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this stateme
November 8, 2024	EX-99	JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Akero Therapeutics, Inc.
November 8, 2024	10-Q	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
November 8, 2024	SC 13G/A	AKRO / Akero Therapeutics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Akero Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00973Y108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate
November 8, 2024	EX-99.1	Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update — First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — Pha Exhibit 99.1 Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update — First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — Phase 3 SYNCHRONY Real-World and Histology studies on track to report results for their respective primary endpoints in 2026 and the first h
November 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 Akero Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commissi
October 17, 2024	SC 13G/A	AKRO / Akero Therapeutics, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 AkeroTherapeuticsInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AKERO THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 00973Y108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule p
September 9, 2024	SC 13G/A	AKRO / Akero Therapeutics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Akero Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00973Y108 (CUSIP Number) August 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
September 9, 2024	EX-99	JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Akero Therapeutics, Inc.
August 9, 2024	EX-99.1	Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update -- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Post Exhibit 99.1 Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH - Presented Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 - - Leadership Team Expanded with Addition of Scott Gangloff as Chi
August 9, 2024	EX-10.1	Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.1 Akero therapeutics, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy of Akero Therapeutics, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers o
August 9, 2024	10-Q	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
August 9, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
June 12, 2024	EX-3.1	Certificate of Amendment of Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-38944) filed on June 12, 2024) Exhibit 3.1 CERTIFICATE OF AMENDMENT OF FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AKERO THERAPEUTICS, INC. Akero Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. The name of the Corporation is Akero Therapeutics, Inc. The
June 12, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission F
May 10, 2024	EX-4.3	Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.3 AKERO THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Cer
May 10, 2024	EX-1.3	Amendment No. 1 to Open Market Sale AgreementSM dated May 10, 2024 by and between Akero Therapeutics, Inc. and Jefferies LLC. Exhibit 1.3 AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM May 10, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Open Market Sale AgreementSM (this “Amendment”) is entered into as of the date first written above by Akero Therapeutics, Inc., a Delaware corporation (the “Company”), and Jefferies LLC (“Agent”), that are parties t
May 10, 2024	EX-10.2	Warrant agreement, dated March 12, 2024 by and between the Registrant and Hercules Private Credit Fund 1 L.P. EXHIBIT 10.2 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN
May 10, 2024	10-Q	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
May 10, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission F
May 10, 2024	EX-4.2	Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.2 AKERO THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certifica
May 10, 2024	S-3ASR	As filed with the Securities and Exchange Commission on May 10, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 10, 2024 Registration No.
May 10, 2024	EX-99.1	Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update — Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2 Exhibit 99.1 Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update — Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 — — Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNC
May 10, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Akero Therapeutics, Inc.
May 10, 2024	EX-10.1	Second Amendment to the Loan and Security Agreement dated February 28, 2024 by and between the Registrant and Hercules Capital, Inc. ACTIVE/129357222 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv).
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Defin
April 16, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant ☐ Check the appropriate box:  Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 18, 2024	EX-4.1	Warrant Agreement, by and between Akero Therapeutics, Inc. and Hercules Private Credit Fund 1 L.P., dated March 12, 2024. Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNS
March 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Akero Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
March 15, 2024	EX-99.1	Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended. EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13D-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.
March 15, 2024	SC 13G	AKRO / Akero Therapeutics, Inc. / GENERAL ATLANTIC LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) March 6, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
March 6, 2024	424B5	TABLE OF CONTENTS Prospectus supplement PAGE About this prospectus supplement S-ii Prospectus supplement summary S-1 Risk factors S-9 Cautionary note regarding forward looking statements S-13 Use of proceeds S-15 Dividend policy S-16 Dilution S-17 Ma Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-256229 Prospectus supplement (To prospectus dated May 18, 2021) 11,000,000 Shares Common stock We are offering 11,000,000 of shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol “AKRO”. On March 5, 2024, the last reported sale price of our common stock was $30.52
March 6, 2024	EX-1.1	Underwriting Agreement, dated as of March 5, 2024, by and between the Company, J.P. Morgan, Morgan Stanley, Jefferies, and Evercore, as representatives of the several underwriters named therein Exhibit 1.1 Akero Therapeutics, Inc. 11,000,000 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement March 5, 2024 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Jefferies LLC Evercore Group L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morgan Stanley & Co
March 6, 2024	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Akero Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Ru Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Akero Therapeutics, Inc.
March 6, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
March 4, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
March 4, 2024	424B5	TABLE OF CONTENTS Prospectus supplement PAGE About this prospectus supplement S-ii Prospectus supplement summary S-1 Risk factors S-9 Cautionary note regarding forward looking statements S-13 Use of proceeds S-15 Dividend policy S-16 Dilution S-17 Ma Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-256229 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offe
March 4, 2024	EX-99.1	Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study 50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approxi Exhibit 99.1 Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study 50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%) 50mg (36%, p<0.01) and 28mg (31%, p<0.01) EFX groups demonstrated ≥2 stage improvement
March 4, 2024	EX-99.2	Forward Looking Statements This presentation and the accompanying oral commentary may contain “forward‐looking statements” of AkeroTherapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigatio Exhibit 99.2 Restoring Balance. Renewing Life. Phase 2b HARMONY Data Presentation: Topline Results from 96 Weeks of Efruxifermin (EFX) Treatment in Patients with Pre-Cirrhotic MASH March 4, 2024 Forward Looking Statements This presentation and the accompanying oral commentary may contain “forward‐looking statements” of AkeroTherapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within th
February 29, 2024	10-K	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 29, 2024	S-8	As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No.
February 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Akero Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commiss
February 29, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Akero Therapeutics, Inc.
February 29, 2024	EX-97.1	Compensation Recovery Policy effective September 13, 2023 EXHIBIT 97.1 AKERO THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY Adopted as of September 13, 2023 Akero Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Pers
February 29, 2024	EX-99.1	Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Exhibit 99.1 Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year finan
February 14, 2024	EX-99.1	Joint Filing Agreement EX-99.1 2 tm245846d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, par value
February 14, 2024	SC 13G/A	AKRO / Akero Therapeutics, Inc. / PFIZER INC - SC 13G/A AKERO Passive Investment SC 13G/A 1 akerotherapeuticsschedule1.htm SC 13G/A AKERO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1 – Exit Filing)* AKERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2023 (Date of Event Which Requ
February 14, 2024	SC 13G/A	AKRO / Akero Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm242424d13sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appr
February 14, 2024	SC 13G	AKRO / Akero Therapeutics, Inc. / RTW INVESTMENTS, LP - AKERO THERAPEUTICS, INC. Passive Investment SC 13G 1 p24-0729sc13g.htm AKERO THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Che
February 14, 2024	SC 13G/A	AKRO / Akero Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
February 13, 2024	SC 13G/A	AKRO / Akero Therapeutics, Inc. / ALKEON CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 akero13ga2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap
February 13, 2024	SC 13G	AKRO / Akero Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0214-akerotherapeuticsinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Akero Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 00973Y108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursua
February 13, 2024	SC 13G/A	AKRO / Akero Therapeutics, Inc. / Avidity Partners Management LP Passive Investment SC 13G/A 1 d1097878513g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap
February 8, 2024	SC 13G	AKRO / Akero Therapeutics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Akero Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00973Y108 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t
February 7, 2024	SC 13G/A	AKRO / Akero Therapeutics, Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - AKERO THERAPEUTICS, INC. Passive Investment SC 13G/A 1 p24-0409sc13ga.htm AKERO THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statemen
December 18, 2023	EX-99.1	Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program Week 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH (F2-F3) to be Reported in March 2024 End-of-Phase 2 FDA Meeting Schedu EX-99.1 Exhibit 99.1 Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program Week 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH (F2-F3) to be Reported in March 2024 End-of-Phase 2 FDA Meeting Scheduled for the first quarter of 2024 to Review Phase 3 Study and Regulatory Path for Treatment of NASH/MASH Patients with Compensate
December 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 Akero Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commiss
November 13, 2023	EX-99.1	Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update — Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 — EX-99.1 Exhibit 99.1 Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update — Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 — SOUTH SAN FRANCISCO, Calif. November 13, 2023 /GLOBE NEWSWIRE/ – Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients wit
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Akero Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commiss
November 13, 2023	10-Q	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
October 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 Akero Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commissi
October 10, 2023	EX-99.2	Safe Harbor and Legal Disclaimers ©2023 AKERO THERAPEUTICS. This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation R Phase 2b SYMMETRY Readout October 10, 2023 Exhibit 99.2 Safe Harbor and Legal Disclaimers ©2023 AKERO THERAPEUTICS. This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including bu
October 10, 2023	EX-99.1	Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization an Exhibit 99.1 Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins 22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worse
September 12, 2023	SC 13G/A	AKRO / Akero Therapeutics Inc / Skorpios Trust Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00973Y108 (CUSIP Number) September 8, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu
August 11, 2023	10-Q	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
August 11, 2023	EX-99.1	Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update — Positive Results from Phase 2b SYMMETRY Cohort D, an expansion cohort of Type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combi EX-99.1 Exhibit 99.1 Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update — Positive Results from Phase 2b SYMMETRY Cohort D, an expansion cohort of Type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 receptor agonist, reported during the second quarter of 2023 — — Phase 3 SYNCHRONY studies on track to begin
August 11, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commissio
June 26, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
June 5, 2023	EX-99.1	Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease Patients treated with EFX for 12 weeks combined with G EX-99.1 Exhibit 99.1 Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone 88% of patients treated
June 5, 2023	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission F
June 5, 2023	EX-99.2	Safe Harbor and Legal Disclaimers This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating EX-99.2 Exhibit 99.2 Restoring Balance. Renewing Life. Corporate Presentation June 2023 Safe Harbor and Legal Disclaimers This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, includ
May 17, 2023	EX-1.1	Underwriting Agreement, dated as of May 16, 2023, by and between the Company and Jefferies LLC, as representative of the several underwriters named therein EX-1.1 Exhibit 1.1 Akero Therapeutics, Inc. 5,238,500 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement May 16, 2023 Jefferies LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Akero Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue an
May 17, 2023	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Akero Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Ru EX-FILING FEES 2 d505061dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Akero Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum A
May 17, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission F
May 17, 2023	424B5	5,238,500 Shares Common Stock 424B5 1 d505061d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-256229 PROSPECTUS SUPPLEMENT (To Prospectus dated May 18, 2021) 5,238,500 Shares Common Stock We are offering 5,238,500 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol “AKRO”. On May 16, 2023, the last reported sale price of ou
May 17, 2023	EX-99.1	Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock EX-99.1 Exhibit 99.1 Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock South San Francisco, CA – May 16, 2023 – Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced the pricing of an underwritten offering of 5,
May 15, 2023	EX-99.1	Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update — Results from Cohort D, an expansion cohort of type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 agonist, EX-99.1 Exhibit 99.1 Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update — Results from Cohort D, an expansion cohort of type 2 diabetic, pre-cirrhotic NASH patients treated with EFX or placebo in combination with a GLP-1 agonist, to be reported during the second quarter of 2023 — — SYNCHRONY Phase 3 studies on track to begin enrolling in the second half of
May 15, 2023	10-Q	Form 10-Q Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One)  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
May 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Akero Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission F
April 28, 2023	DEF 14A	definitive proxy statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant  Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Defin
April 10, 2023	SC 13G	AKRO / Akero Therapeutics Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - AKERO THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) March 30, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant t
March 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 Akero Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
March 29, 2023	EX-99.1	Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH The planned Phase 3 program consists of three trials, SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes t EX-99.1 Exhibit 99.1 Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH The planned Phase 3 program consists of three trials, SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes to evaluate the safety and efficacy of efruxifermin (EFX) in patients with NASH SYNCHRONY Histology and SYNCHRONY Real-World are e
March 17, 2023	424B5	Up to $200,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256229 PROSPECTUS SUPPLEMENT (To Prospectus dated May 18, 2021) Up to $200,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the Sale Agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement. In acco
March 17, 2023	EX-1.1	Open Market Sale AgreementSM, by and between Akero Therapeutics, Inc. and Jefferies LLC, dated March 17, 2023 EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM March 17, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Akero Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s
March 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 Akero Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
March 17, 2023	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Akero Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Ru EX-FILING FEES 2 d449725dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Akero Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum A
March 17, 2023	EX-4	Exhibit 4.2 EXHIBIT 4.2 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Akero Therapeutics, Inc.(“Akero,” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Fourth Amended
March 17, 2023	10-K	Form 10-K Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Akero Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
March 17, 2023	EX-99.1	Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results EX-99.1 Exhibit 99.1 Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results SOUTH SAN FRANCISCO, March 17, 2023 /GLOBE NEWSWIRE/ – Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial result
March 17, 2023	S-8	Power of Attorney (included on signature page). S-8 As filed with the Securities and Exchange Commission on March 17, 2023 Registration No.
March 17, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Akero Therapeutics, Inc.
February 14, 2023	EX-1	Joint Filing Agreement EX-1 2 ex-1.htm JOINT FILING AGREEMENT Atlas Venture Fund XI, L.P. SC 13G/A Exhibit A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Akero Therapeutics, Inc. and further
February 14, 2023	SC 13G	AKRO / Akero Therapeutics Inc / BAKER BROS. ADVISORS LP - SC 13G Passive Investment SC 13G 1 tm234999d6sc13g.htm SC 13G SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. )* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate
February 14, 2023	SC 13G/A	AKRO / Akero Therapeutics Inc / Atlas Venture Fund XI, L.P. - AMENDMENT TO FORM SC 13G Passive Investment SC 13G/A 1 akro-sc13ga123122.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Akero Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 00973Y 108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This
February 14, 2023	SC 13G	AKRO / Akero Therapeutics Inc / Redmile Group, LLC - SC 13G Passive Investment SC 13G 1 tm236041d12sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) AKERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appro
February 14, 2023	EX-99.1	AGREEMENT EX-99.1 2 tm234999d6ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Akero Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2023 BAKER BROS. ADVI
February 14, 2023	EX-99.1	Joint Filing Agreement EX-99.1 2 tm236041d12ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001
February 14, 2023	SC 13G/A	AKRO / Akero Therapeutics Inc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d994238613g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the app
February 14, 2023	SC 13G/A	AKRO / Akero Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G/A, AMENDMENT #2 Passive Investment SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #2 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Akero Therapeutics, Inc. (Title
February 13, 2023	SC 13G/A	AKRO / Akero Therapeutics Inc / ALKEON CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
February 6, 2023	SC 13G/A	AKRO / Akero Therapeutics Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Akero Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00973Y108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
December 5, 2022	SC 13G/A	AKRO / Akero Therapeutics Inc / Skorpios Trust Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00973Y108 (CUSIP Number) December 1, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
November 4, 2022	10-Q	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
November 4, 2022	EX-99.1	Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update EX-99.1 Exhibit 99.1 Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, November 4, 2022 /GLOBE NEWSWIRE/ — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial resul
November 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commissi
September 16, 2022	EX-1.1	Underwriting Agreement, dated as of September 14, 2022, by and between the Company, J.P. Morgan, Morgan Stanley and Jefferies, as representatives of the several underwriters named therein EX-1.1 2 d386189dex11.htm EX-1.1 Exhibit 1.1 Akero Therapeutics, Inc. 7,692,308 Shares of Common Stock, par value $0.0001 per share Underwriting Agreement September 14, 2022 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Jefferies LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morgan
September 16, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commis
September 16, 2022	SC 13G	AKRO / Akero Therapeutics Inc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
September 15, 2022	424B5	7,692,308 Shares Common stock Prospectus supplement J.P. Morgan Morgan Stanley Jefferies Canaccord Genuity H.C. Wainwright & Co. Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-256229 Prospectus supplement (To prospectus dated May 18, 2021) 7,692,308 Shares Common stock We are offering 7,692,308 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol ?AKRO?. On September 14, 2022, the last reported sale price of our common stock was $27.70
September 15, 2022	SC 13D/A	AKRO / Akero Therapeutics Inc / venBio Global Strategic Fund II L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Ad
September 13, 2022	EX-99.1	In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks 50mg (41%) and 28mg (39%) groups demonstrated ≥1 stage improvement in fibros Exhibit 99.1 In Akero Therapeutics? Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks 50mg (41%) and 28mg (39%) groups demonstrated ?1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution without worseni
September 13, 2022	424B5	$175,000,000 Common stock Prospectus supplement J.P. Morgan Morgan Stanley Jefferies Canaccord Genuity H.C. Wainwright & Co. Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-256229 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offe
September 13, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2022 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commis
September 13, 2022	EX-99.2	Safe Harbor ©2022 AKERO THERAPEUTICS. This presentation and the accompanying oral commentary may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securiti Phase 2b HARMONY Study Results Restoring Balance. Renewing Life. September 13, 2022 Exhibit 99.2 Safe Harbor ?2022 AKERO THERAPEUTICS. This presentation and the accompanying oral commentary may contain ?forward-looking statements? of Akero Therapeutics, Inc. (?we,? ?us,? ?our,? ?Akero? or the ?Company?) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our busi
August 5, 2022	10-Q	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
August 5, 2022	EX-10.2	Loan and Security Agreement dated as of June 15, 2022 by and between the Registrant and Hercules Capital, Inc. (Incorporated by reference to Exhibit 10.2 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38944 filed on August 5, 2022). EXHIBIT 10.2 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of June 15, 2022 and is entered into by and among AKERO THERAPEUTICS,
August 5, 2022	EX-10.3	Warrant, dated June 15, 2022 by and between the Registrant and Hercules Private Global Venture Growth Fund I L.P. (Incorporated by reference to Exhibit 10.3 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38944 filed on August 5, 2022). EXHIBIT 10.3 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN
August 5, 2022	EX-10.4	Warrant, dated June 15, 2022 by and between the Registrant and Hercules Capital, Inc. (Incorporated by reference to Exhibit 10.4 of the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38944 filed on August 5, 2022). EXHIBIT 10.4 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUN
August 4, 2022	EX-99.1	Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, August 4, 2022 /GLOBE NEWSWIRE/ ? Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for t
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
June 28, 2022	SC 13G	AKRO / Akero Therapeutics Inc / PFIZER INC - SC 13G AKERO THERAPEUTICS Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* AKERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00973Y108 (CUSIP Number) June 17, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
June 16, 2022	EX-99.1	Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million $25 Million Equity Investment by Pfizer at $9.90 Per Share Term Loan Facility from Hercules Providing Up to $10 Exhibit 99.1 Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million $25 Million Equity Investment by Pfizer at $9.90 Per Share Term Loan Facility from Hercules Providing Up to $100 Million If Fully Drawn, Akero Cash Runway Extended One Full Year From Previously Announced Q3 2023 to Q3 2024 SOUTH SAN FRANCISCO, June
June 16, 2022	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Akero Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Ru EX-FILING FEES 2 d339101dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Akero Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum A
June 16, 2022	424B5	2,525,252 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-256229 PROSPECTUS SUPPLEMENT (to Prospectus dated May 18, 2021) 2,525,252 Shares of Common Stock We are offering 2,525,252 shares of our common stock directly to the investor, Pfizer Inc., in this offering at a price per share of $9.90. This offering is being made without an underwriter or a placement agent and we ar
June 16, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 15, 2022 AKERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
June 16, 2022	EX-10.1	Securities Purchase Agreement dated as of June 15, 2022 by and between Akero Therapeutics, Inc. and Pfizer Inc. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of June 15, 2022, between Akero Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the ?Company?), and Pfizer Inc., a corporation organized under the laws of the State of Delaware (the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in
June 8, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission F
June 8, 2022	EX-99.1	Safe Harbor This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, oper EX-99.1 Exhibit 99.1 Restoring Balance. Renewing Life. Corporate Presentation June 2022 Safe Harbor This presentation may contain “forward-looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to
June 3, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission F
May 6, 2022	10-Q	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
May 6, 2022	EX-99.1	Akero Therapeutics Reports First Quarter 2022 Financial Results Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year Exhibit 99.1 Akero Therapeutics Reports First Quarter 2022 Financial Results Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year SOUTH SAN FRANCISCO, May 6, 2022 /GLOBE NEWSWIRE/ ? Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet me
May 6, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2022 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission Fi
April 28, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 tm223576-1def14a.htm TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of
March 2, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-
March 2, 2022	EX-FILING FEES	Filing Fee Table. EX-FILING FEES 4 tm227647d1ex-filingfee.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Akero Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rat
March 2, 2022	S-8	As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No.
February 25, 2022	EX-21.1	List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 of the Registrant's Annual Report on Form 10-K (File No. 001-38944) filed on February 25, 2022) Exhibit 21.1 ? SUBSIDIARIES ? ? ? ? Subsidiary Jurisdiction of Incorporation ? ? ? Akero Securities Corporation ? Massachusetts ?
February 25, 2022	EX-10.10	Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.10 AKERO THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy of Akero Therapeutics, Inc. (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers
February 25, 2022	10-K	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents 33 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 25, 2022	EX-99.1	Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year Exhibit 99.1 Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This Year SOUTH SAN FRANCISCO, February 25, 2022 /GLOBE NEWSWIRE/ - Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases ma
February 25, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2022 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commiss
February 14, 2022	SC 13G/A	AKRO / Akero Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G (AMENDMENT #1) Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* (Name of Issuer) Akero Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $0.000
February 14, 2022	EX-99.1	Joint Filing Agreement EX-99.1 2 tm226094d15ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001
February 14, 2022	SC 13G/A	AKRO / Akero Therapeutics Inc / ALKEON CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
February 14, 2022	SC 13G/A	AKRO / Akero Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Akero Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
February 11, 2022	EX-1	Joint Filing Agreement Atlas Venture Fund XI, L.P. SC 13G/A Exhibit A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Akero Therapeutics, Inc. and further agree that this agreement be included a
February 11, 2022	SC 13G/A	AKRO / Akero Therapeutics Inc / Atlas Venture Fund XI, L.P. - AMENDMENT TO SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Akero Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 00973Y 108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule
February 4, 2022	SC 13G	AKRO / Akero Therapeutics Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Akero Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
December 13, 2021	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi
December 13, 2021	SC 13G	AKRO / Akero Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Akero Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $0.0001
December 10, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commissi
November 12, 2021	EX-99.1	Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment Most EFX-treated patients with end-of treatment biopsies showed i Exhibit 99.1 Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment Most EFX-treated patients with end-of treatment biopsies showed improvements in features of steatohepatitis (35 of 40; 87%) and/or fibrosis (32 of 40; 80%), after only 16 weeks Histological improvements
November 12, 2021	EX-99.1	Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Exhibit 99.1 Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) - Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported third quarter financial results for the period ending
November 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commiss
November 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commiss
November 12, 2021	10-Q	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents 33 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? ? ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended September 30, 2021 OR ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File No.
September 9, 2021	EX-99.1	A Global Disease, A Pioneering Treatment Corporate Presentation September 2021 Exhibit 99.1 A Global Disease, A Pioneering Treatment Corporate Presentation September 2021 - CONFIDENTIAL - CORPORATE HIGHLIGHTS 2 ? Human FGF21 analog addresses all core aspects of NASH pathology ? Engineered for optimal activity and convenient once - weekly dosing ? We believe Phase 2a BALANCED study results in biopsy - confirmed NASH patients among strongest data in field for both F1 - F3 and
September 9, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commiss
August 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commissio
August 13, 2021	10-Q	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents 33 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? ? ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2021 OR ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File No.
August 13, 2021	EX-99.1	Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update EX-99.1 2 tm2124964d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, August 13, 2021 /GLOBE NEWSWIRE/ - Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported second quarter
July 14, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
June 30, 2021	SC 13G	AKRO / Akero Therapeutics Inc / Skorpios Trust Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00973Y108 (CUSIP Number) June 21, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
June 29, 2021	SC 13D/A	AKRO / Akero Therapeutics Inc / ATP Life Science Ventures, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00973Y 108 (CUSIP Number) Daniel P. Finkelman General Counsel Apple Tree Partners 230 Park Avenue, 28th Floor New York, NY 10169 (212) 46
June 25, 2021	EX-99.1	Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin ( Exhibit 99.1 Akero Therapeutics Presents at the American Diabetes Association?s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients Analyses Show that the Magnitude of Reductions in Markers of Liver Injury and Fibrogenesis, as w
June 25, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
June 21, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
June 21, 2021	EX-99.1	Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH Analyses also Show that C Exhibit 99.1 Akero Therapeutics Presents Analyses at the 2021 International Liver Congress Showing Normalization of Liver Fat Substantially Reduced Markers of Liver Injury and Fibrosis, and Greatly Increased Probability of Resolving NASH Analyses also Show that Combining a Threshold for ALT Reduction of ?17 U/L with Normalization of Liver Fat Improves Predictive Power for Resolution of NASH with 1
June 2, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission F
May 18, 2021	EX-1.2	Equity Distribution Agreement, dated as of May 18, 2021, between the Registrant and J.P. Morgan Securities LLC EX-1.2 2 tm2116594d2ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 DISTRIBUTION AGREEMENT May 18, 2021 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Akero Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement with J.P. Morgan Securities LLC, as agent and/or principal under any Terms Agreement (as defined in Section 1(a) below) (“you” o
May 18, 2021	S-3ASR	As filed with the Securities and Exchange Commission on May 18, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 18, 2021 Registration No.
May 18, 2021	EX-4.4	Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.4 AKERO THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Cer
May 18, 2021	EX-4.3	Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.3 AKERO THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certifica
May 13, 2021	EX-99.2	Corporate slide presentation of Akero Therapeutics, Inc., furnished herewith Exhibit 99.2 A Global Disease, A Pioneering Treatment Corporate Presentation May 2021 CORPORATE HIGHLIGHTS - CONFIDENTIAL - EXTENSIVE DEVELOPMENT AND COMMERCIALIZATION EXPERIENCE INVOLVED IN 20+ MEDICINE APPROVALS Andrew Cheng, MD, PhD \| President & CEO 19 years at Gilead Chief Medical Officer & HIV Division Head Major role in 11 NDA/MAA approvals Jonathan Young, PhD, JD \| Founder, EVP & COO Over
May 13, 2021	10-Q	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents 33 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2021 OR ? ? ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File No.
May 13, 2021	EX-99.1	Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update EX-99.1 2 tm2116108d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, May 13, 2021 /GLOBE NEWSWIRE/ - Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported first quarter fina
May 13, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission F
May 7, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Ad
April 27, 2021	DEF 14A	Definitive Proxy Statement TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ?
April 26, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
April 13, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
April 13, 2021	EX-99.1	A Global Disease, A Pioneering Treatment Corporate Presentation April 2021 Exhibit 99.1 A Global Disease, A Pioneering Treatment Corporate Presentation April 2021 - CONFIDENTIAL - CORPORATE HIGHLIGHTS 2 • Human FGF21 analog addresses all core aspects of NASH pathology • Engineered for optimal activity and convenient once - weekly dosing • We believe Phase 2a BALANCED study results among strongest data in field for both F1 - F3 and cirrhotic (F4) patients • Generally well
March 23, 2021	8-K	Other Events 8-K 1 tm219778d38k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdicti
March 22, 2021	EX-99.1	Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C -- 33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH -- -- 25% of Exhibit 99.1 Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C - 33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH - - 25% of EFX patients (3 of 12) showed NASH resolution - - Rapid fibrosis improvement in cirrhotic patients after only 16 weeks of EFX treatment, th
March 22, 2021	EX-99.2	Slide presentation of Akero Therapeutics, Inc., filed herewith Exhibit 99.2 A Global Disease, A Pioneering Treatment Cohort C Readout: 16-Week Study of EFX in Cirrhotic NASH Patients (F4) March 22, 2021 SAFE HARBOR This presentation may contain ?forward-looking statements? of Akero Therapeutics, Inc. (?we,? ?us,? ?our,? ?Akero? or the ?Company?) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, an
March 22, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
March 18, 2021	S-8	- FORM S-8 As filed with the Securities and Exchange Commission on March 18, 2021 Registration No.
March 16, 2021	10-K	Annual Report - 10-K Table of Contents 33 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 16, 2021	EX-21.1	List of Subsidiaries of the Registrant EX-21.1 2 akro-20201231ex211384978.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Akero Securities Corporation Massachusetts
March 16, 2021	EX-99.1	Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results SOUTH SAN FRANCISCO, March 16, 2021 /GLOBE NEWSWIRE/ - Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported fourth quarter and full year financial results for the period ending Decemb
March 16, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
March 12, 2021	EX-3.1	Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as amended (File No. 001-38944)) as filed with the SEC on March 12, 2021. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF AKERO THERAPEUTICS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may
March 12, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commission
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2) Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y 108 (CUSIP Number) De
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akero Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securitie UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akero Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 00973Y 108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule
February 16, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Akero Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) (CUSIP Number) Dec UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Akero Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
February 16, 2021	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Akero Therapeutics, I
February 11, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ___) Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
February 5, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of S SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00973Y 108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
January 11, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commissi
January 11, 2021	EX-99.1	A Global Disease, A Pioneering Treatment Akero Therapeutics, Inc. JP Morgan Presentation January 2021 Exhibit 99.1 A Global Disease, A Pioneering Treatment Akero Therapeutics, Inc. JP Morgan Presentation January 2021 - CONFIDENTIAL - SAFE HARBOR This presentation may contain “forward - looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Compa ny”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and fin
November 16, 2020	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2020 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commiss
November 16, 2020	EX-99.1	A Global Disease, A Pioneering Treatment Akero Therapeutics, Inc. Corporate Presentation November 2020 Exhibit 99.1 A Global Disease, A Pioneering Treatment Akero Therapeutics, Inc. Corporate Presentation November 2020 - CONFIDENTIAL - SAFE HARBOR This presentation may contain “forward - looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Compa ny”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and fi
November 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commiss
November 12, 2020	EX-99.1	Akero Therapeutics Reports THIRD Quarter 2020 Financial Results Exhibit 99.1 Akero Therapeutics Reports THIRD Quarter 2020 Financial Results SOUTH SAN FRANCISCO, Calif., November 12, 2020 - Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today reported third quarter financial results for
November 12, 2020	10-Q	33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
October 15, 2020	8-K	Financial Statements and Exhibits, Other Events 8-K 1 tm2033079-18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2020 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdi
October 15, 2020	EX-99.1	A Global Disease, A Pioneering Treatment Akero Therapeutics, Inc. Corporate Presentation October 2020 Exhibit 99.1 A Global Disease, A Pioneering Treatment Akero Therapeutics, Inc. Corporate Presentation October 2020 - CONFIDENTIAL - SAFE HARBOR This presentation may contain “forward - looking statements” of Akero Therapeutics, Inc. (“we,” “us,” “our,” “Akero” or the “Compa ny”) within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and fin
September 10, 2020	SC 13G/A	AKRO / Akero Therapeutics, Inc. / JANUS HENDERSON GROUP PLC - JANUS HENDERSON GROUP PLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00973Y108 (CUSIP Number) August 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
September 9, 2020	SC 13D/A	AKRO / Akero Therapeutics, Inc. / venBio Global Strategic Fund II L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Ad
August 12, 2020	EX-99.1	Akero Therapeutics Reports SECOND Quarter 2020 Financial Results Exhibit 99.1 Akero Therapeutics Reports SECOND Quarter 2020 Financial Results SOUTH SAN FRANCISCO, Calif., August 12, 2020 - Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today reported second quarter financial results for
August 12, 2020	10-Q	Quarterly Report - 10-Q Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
August 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2020 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorporation) (Commissio
August 7, 2020	RW	- RW August 7, 2020 VIA EDGAR Division of Corporation Finance Office of Healthcare & Insurance Securities and Exchange Commission 100 F Street, N.
July 14, 2020	SC 13D/A	TTNP / Titan Pharmaceuticals, Inc. / Apple Tree Partners IV, L.P. - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment Amendment No. 1 to Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00973Y 108 (CUSIP Number) Kristin Howell Fund Controller Apple Tree Partners 230 Park Avenue, 28th Floor
July 9, 2020	424B4	Per share Total Public offering price $ 36.00 $ 188,213,976 Underwriting discounts and commissions(1) $ 2.16 $ 11,292,839 Proceeds to Akero Therapeutics, Inc., before expenses $ 33.84 $ 176,921,137 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(4) Registration No.
July 8, 2020	SC 13D/A	AKRO / Akero Therapeutics, Inc. / Venbio Global Strategic Fund, L.p. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Akero Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00973Y108 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Ad
July 7, 2020	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2020 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38944 81-5266573 (State or other jurisdiction of incorpo
July 7, 2020	S-1MEF	- S-1MEF As filed with the Securities and Exchange Commission on July 7, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 81-5266573 (State or other jurisdiction of (Primary Standard Industrial (I.R.
July 6, 2020	EX-1.1	Form of Underwriting Agreement EX-1.1 2 a2242026zex-11.htm EX-1.1 Exhibit 1.1 Akero Therapeutics, Inc. [-] Shares of Common Stock, par value $0.0001 per share Underwriting Agreement [-], 2020 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Jefferies LLC Evercore Group L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Mor

DE:0K4	€ 38.99
IT:1AKRO	€ 44.76

AKRO / Akero Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings